
Kamel Khalili, Excision BioTherapeutics
FDA clears first-of-its-kind trial to see if CRISPR gene editing can cure HIV
The FDA has cleared a company trying to use CRISPR gene-editing to cure HIV to begin clinical trials.
The study, run by the startup Excision BioTherapeutics, will likely begin early next year, CMO Lisa Danzig said, after final details are hashed out. It will involve three groups of three healthy HIV patients, with each group given a sequentially higher dose as the company tests the safety of the new therapy.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters